# 学位論文内容の要旨

博士の専攻分野の名称　博士（医　学）　氏 名　楊　子健

学 位 論 文 題 名

Studies on the drug resistance mechanisms in hepatocellular carcinoma

（肝細胞癌の薬剤耐性機構の解析）

**Background and Purpose**

Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide. With several successful clinical trials, multi-tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs) are commonly used in clinical practice of unresectable HCC nowadays. TKIs are a class of drugs that inhibit tyrosine kinases activity which implicated in tumorigenesis and progression. ICIs are monoclonal antibodies that release the inhibitory brakes of T cells, resulting in antitumor immune responses. In 2018, a novel TKIs of lenvatinib was approved for unresectable HCC in Japan. Quite recently, the combination therapy of ICIs of atezolizumab which is a programmed death ligand 1 (PD-L1) antibody and bevacizumab which is a VEGF-A antibody have been approval refer to successful phase III clinical trial.

Despite there are many effective treatments as lenvatinib and atezolizumab plus bevacizumab available for unresectable HCC, relapse after once responding to systemic therapies still a pressing issue. Regardless of the treatment response, all patients finally get progression in HCC. Thus, it is important to clarify the reasons of progression after once response to lenvatinib as well as atezolizumab plus bevacizumab.

Some previous studies have concentrated on predicting of treatment response threw baseline serum growth factor levels, however the data of sequential changes in growth factors during systemic treatment, especially with respect to progressive disease (PD), have not been completely clarified. In the first chapter of this study, from the aspect of patient serum growth factors, we aimed to comprehend factors with respect to PD and to investigate the sequential changes in serum growth factors during lenvatinib treatment for unresectable HCC. In chapter 2, we aimed to analyze the changes in growth factors during the atezolizumab plus bevacizumab treatment for unresectable HCC to have an insight in mechanism of acquire resistance during atezolizumab plus bevacizumab treatment for HCC. In some basic research regarding lenvatinib resistance mechanisms in HCC cell lines, in the aspect of changes in kinase, cytokine, and microRNA profile, some molecules of great importance have been clarified. However, in the aspect of alteration in gene expression, mechanisms of HCC cells acquire lenvatinib resistance have not been clarified well. Therefore, in Chapter 3, we established lenvatinib resistant cells and analysis the underlying mechanism regarding resistant to lenvatinib in gene expression level using DNA microarray and pathway analysis, aim to seize prospective critical genes in lenvatinib resistance cells.

**Chapter 1**

**Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma**

**Subjects and Methods**

This study is a single center retrospective observational study. In this chapter, we included unresectable hepatocellular carcinoma patients who received lenvatinib treatment between April 2018 and May 2021 in Hokkaido University Hospital and excluded patients who were concomitant treated with other anticancer agents or received concomitance chemoembolization treatment. We detected patient serum growth factor levels by ELISA at each of the three points (baseline, best overall response, and PD point) and analyzed the connection between patient treatment response, patient characteristics, post progression survivals and the changes in serum growth factors.

**Results**

In this study, we include 58 patients, and a total of 8, 24, 18, and 8 patients experienced best overall response of CR, PR, SD, and PD, respectively. Baseline serum ANG-2 levels, relative dose intensity and age were proved associated with lenvatinib treatment response. During the treatment of lenvatinib,

patients can be divided in to four groups according to the changing patterns of serum levels of ANG-2, EGF and HGF. As other prognosis related factors are similar among groups, patient post progression survival was significantly different among four groups.

**Discussion and Conclusion**

Our findings demonstrate that the pattern of development of resistance to lenvatinib varies and might determine the prognosis of patients with unresectable HCC. Thus, the evaluation of baseline patient characteristics and the changes in growth factors during lenvatinib could predict treatment response and PPS and can be used to determine subsequent treatments.

**Chapter 2**

**Changes in Serum Growth Factors during atezolizumab plus bevacizumab treatment in Patients with Unresectable Hepatocellular Carcinoma**

**Subjects and Methods**

This study is a single center retrospective observational study. In this chapter, we included unresectable HCC patients who received lenvatinib treatment between April 2018 and May 2021 in Hokkaido University Hospital and excluded patients who were concomitant treated with other anticancer agents or received concomitance chemoembolization treatment. We detected patient serum growth factor levels by ELISA at each of the three points (baseline, best overall response, and PD point) and analyzed the connection between patient treatment response, patient characteristics and the changes in serum growth factors.

**Results**

In this study, we include 46 patients, and a total of 4, 9, 19, and 14 patients experienced best overall response of CR, PR, SD, and PD, respectively. Baseline serum growth factor levels were similar between patients with or without disease controls and also similar between patients with or without OR. FGF-19 significantly increased at best overall response point, on the contrary, ANG-2 significantly decreased at best overall response point. VEGF-D, and ANG-2 significantly increased at PD point compared with that at best overall response point.

**Discussion and Conclusion**

VEGF-D and ANG-2 significantly increased at PD point compared with best overall response point. Increased VEGF-D and ANG-2 might be contributed to obtained resistance to atezolizumab plus bevacizumab for unresectable HCC and might be target molecule in the subsequent salvage therapy.

**Chapter 3**

**Mechanism contributing to lenvatinib resistance in hepatocellular carcinoma cells.**

**Subjects and Methods**

In this chapter, we aimed to establish lenvatinib resistant cells (Huh7-LenR cells) by continuously exposure human hepatocellular carcinoma cell line of Huh7 cells to lenvatinib. After ensuring that the Huh7-LenR cells was properly resistant to lenvatinib *in vitro* and *in vivo*, we investigate sensitivity of Huh7-LenR cells to other anti-HCC drugs and tried to investigate the key molecule that associated with resistance to lenvatinib by Microarray and pathway analysis. Next, we established candidate gene overexpressing HCC cells using lentivirus, and analyzed their resistance to lenvatinib.

**Results**

Established Huh7-LenR cells showed resistant to lenvatinib *in vitro* ang *in vivo*. We established Huh7-LenR cells which showed that Huh7-LenR cells have a lower sensitivity comparing with Huh7 cells under the treatment of various TKIs containing sorafenib, cabozantinib and regorafenib. We focused on candidate gene associates with lenvatinib resistance according to results of microarray analysis and pathway analysis. But individually knock down or over expression of GPX8 has no impact on the sensitivity of Huh7 derived cells to lenvatinib.

**Discussion and Conclusion**

In present study, we established Huh7-LenR cells which is resistant to lenvatinib treatment and find that gene expression was quite different in Huh7-LenR cells compared with Huh7 cells. Our results showed that GPX8 was a potential candidate that significantly up regulated in Huh7-LenR cells compared with control Huh7 cells. However, individually knock down and over expression of GPX8 indicate that GPX8 was not the only key reason of resistance in Huh7-LenR cells. So, in future, we will further focus on other candidates according to results of microarray and pathway analysis.